BTX Share Price

Open 3.30 Change Price %
High 3.30 1 Day -0.12 -3.60
Low 3.20 1 Week -0.25 -7.23
Close 3.21 1 Month -0.67 -17.27
Volume 280885 1 Year 0.71 28.40
52 Week High 4.01
52 Week Low 2.02
BTX Important Levels
Resistance 2 3.30
Resistance 1 3.26
Pivot 3.24
Support 1 3.16
Support 2 3.12
AMEX USA Most Active Stocks
PAL 0.05 -50.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
RBY 0.03 -70.00%
NAK 2.46 -2.77%
NAK 2.46 -2.77%
NGD 4.16 1.22%
NGD 4.16 1.22%
PBTH 8.23 0.37%
BTI 116.76 2.29%
AMEX USA Top Gainers Stocks
GGR 0.02 100.00%
ATC 0.37 60.87%
ATC 0.37 60.87%
ATC 0.37 60.87%
ATC 0.37 60.87%
MBA 0.20 25.00%
MBA 0.20 25.00%
MBA 0.20 25.00%
GMO 0.38 22.58%
IG 7.68 22.49%
AMEX USA Top Losers Stocks
RBY 0.03 -70.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
QBC 0.20 -33.33%
ATL 0.06 -25.00%
ATL 0.06 -25.00%
SNT 0.12 -20.00%
INV 0.14 -17.65%
INV 0.14 -17.65%

BioTime, Inc. (AMEX: BTX)

BTX Technical Analysis 1.5
As on 19th Jan 2017 BTX Share Price closed @ 3.21 and we RECOMMEND Buy for LONG-TERM with Stoploss of 3.09 & Sell for SHORT-TERM with Stoploss of 3.48 we also expect STOCK to react on Following IMPORTANT LEVELS.
BTX Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
BTX Other Details
Segment EQ
Market Capital 186688976.00
Sector Healthcare
Industry Biotechnology
Offical website
BTX Address
1301 Harbor Bay Parkway
Alameda, CA 94502
United States
Phone: 510-521-3390
Fax: 510-521-3389
BTX Latest News
Additional Data From BioTime's OpRegenĀ® Clinical Trial in Dry-AMD to be ...   Business Wire (press release)   - 19th Jan 17
BioTime, Inc. (BTX) Stake Held by Destination Wealth Management   The Cerbat Gem   - 19th Jan 17
MA Watch on Shares of BioTime Inc. (BTX)   Yankee Analysts   - 18th Jan 17
The BioTime, Inc. (BTX) Lowered to Hold at the Zacks Investment Research   DailyQuint   - 14th Jan 17
BioTime, Inc. Reports Third Quarter Results and Recent Clinical Progress   Business Wire (press release)   - 04th Nov 16
BioTime, Inc. to Announce Third Quarter Results on November 3, 2016   Business Wire (press release)   - 24th Oct 16
BioTime, Inc. Reports Second Quarter Results and Recent Corporate Accomplishments   Business Wire (press release)   - 10th Aug 16
BioTime, Inc. Announces Full Exercise and Closing of Underwriters' Over ...   Business Wire (press release)   - 05th Jul 16
Adjustments Affecting BioTime, Inc. Common Share Purchase Warrants Expiring ...   Business Wire (press release)   - 13th Jan 16
BioTime, Inc. and Hepregen Corporation Form Ascendance Biotechnology, Inc. to ...   Business Wire (press release)   - 06th Nov 15
Interactive Technical Analysis Chart BioTime, Inc. ( BTX AMEX USA )
Java support must be enabled in order to display FnCharts.
You can download Java from
Your Comments and Response on BioTime, Inc.
BTX Business Profile
BioTime, Inc., a biotechnology company, is engaged in the research and product development in the field of regenerative medicine. The company primarily focuses on regenerative medicine, which refers to therapies based on human embryonic stem cell and induced pluripotent stem cell technology designed to rebuild cell and tissue function lost due to degenerative disease or injury. It develops and markets research products in the field of stem cells, including an array of proprietary PureStem cell lines and associated ESpan culture media, cGMP-capable human embryonic stem cell lines, and differentiation kits, as well as offers Hextend, a blood plasma volume expander to treat hypovolemia in surgery, emergency trauma treatment, and other applications. The company is developing Renevia, a biocompatible, implantable hyaluronan, and collagen-based matrix for cell delivery in human clinical applications; and stem cell-based therapies for retinal and neurological disorders. It also develops HyStem hydrogels, such as ReGlyde, a cross-linked thiol-modified hyaluronan hydrogel to manage and protect tendon injuries; and Premvia, a hydrogel formulation to manage wounds, as well as PanC-Dx, a non-invasive cancer products for use in detecting breast, bladder, and lung cancers. In addition, the company markets GeneCards, a human gene database. Further, it is developing an integrated database suite to complement GeneCards that would include the LifeMap database of embryonic development, stem cell research, and regenerative medicine, as well as MalaCards, the human disease database. Additionally, the company develops cell based therapeutic products for diseases, such as neurological disorders, age related macular degeneration, orthopedic disorders, and cardiovascular disease and related ischemic disorders. BioTime, Inc. was founded in 1990 and is headquartered in Alameda, California.